CombiMatrix

CombiMatrix Corporation focuses on proprietary technologies, products, and services in the fields of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include platforms for generating user-defined in-situ synthesis and oligonucleotide arrays to identify and determine the functions of genes, gene mutations, and proteins. The company’s products and services encompass the CustomArray platform, an oligonucleotide array for genetic research; the DNA Array Synthesizer, an instrument enabling researchers to manufacture DNA arrays according to their specifications; stripping reagents, which allow researchers to reuse microarrays; the ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays for research and molecular diagnostic applications. It also provides proprietary molecular synthesis and screening methods for discovering potential new drugs. Additionally, it operates as a diagnostic reference laboratory, offering genetic diagnostic services using bacterial artificial chromosome arrays that enable genetic analysis for doctors, hospitals, and clinics. The company has developed a series of compounds aimed at addressing various tumor-related diseases. It is also involved in the development, manufacturing, and sales of biosensor systems and technologies for defense and homeland security applications. The company sells its products and services directly, through partners, and via distributors to customers in the United States, Europe, and Asia.